Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

– Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients –

BOSTON, October 16, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remain a member of the Board of Directors.

"The Board of Directors selected Tammi Gaskins to be Ironwood's next CEO because she is a proven leader with a deep understanding of the business, culture and late-stage pipeline. Tammi was instrumental in driving the turnaround of LINZESS® this year, returning it to blockbuster status and growth. She is uniquely positioned to build upon the strong momentum Ironwood has delivered so far in 2026, and to lead the company through its next phase of growth," said Julie McHugh, Chair of the Ironwood Board of Directors.

Tammi has been a leader in Ironwood's commercial organization since joining the company in 2020 playing a critical role establishing LINZESS as the number one prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). She has also led commercial development efforts for apraglutide, a potential best-in-class, once-weekly GLP-2 analog in Phase 3 development for the treatment of adults with short bowel syndrome with intestinal failure (SBS-IF). Prior to joining Ironwood, Tammi held commercial leadership roles of increasing responsibilities during a 20-year tenure at AstraZeneca.

"It is an honor to be named Ironwood's next CEO, and I would like to thank Tom and the Board of Directors for their leadership and support," said Gaskins. "I am excited to continue working with our talented team to bring innovation to patients living with GI and rare diseases. This has been a turnaround year for Ironwood as we have worked to maximize the value of LINZESS and strengthen our balance sheet while advancing the confirmatory STARS-2 clinical trial of apraglutide in SBS-IF. With each step we are shaping Ironwood for the future, working to bring treatment advancements to patients and creating value for shareholders. I look forward to helping Ironwood continue to grow as we extend this momentum into 2027 and beyond."